Longitude Capital closes second life sciences fund with $385M

Friday, October 12, 2012 12:13 PM

Longitude Capital has closed the Longitude Venture Partners II, a $385 million venture capital fund dedicated to investments in drug development and medical technology. 

The Fund, which exceeded its target of $325 million, is the successor to Longitude's inaugural investment vehicle, Longitude Venture Partners, which closed in July 2008 at $325 million and exceeded its target of $250 million. The first fund has invested in nearly 20 companies including Amarin, Aptus Endosystems, AqueSys, CardioDx, Civitas Therapeutics, Corcept Therapeutics, Jazz Pharmaceuticals and NxStage Medical.

"Longitude's venture growth strategy in life sciences focuses on building balanced portfolios of primarily mid-stage to commercial-stage companies with clinically de-risked assets and three-to-five year liquidity horizons,” said Juliet Tammenoms Bakker, co-founder and managing director, Longitude. “Our approach has enabled strong absolute and relative performance driven by multiple near-term realizations across our portfolio.  We appreciate the strong support from our existing institutional and individual investors, and are delighted to welcome several new top tier institutional investors into this Fund."

Patrick Enright, Longitude co-founder and managing director, added, "We believe that Longitude Capital's investment strategy is well-suited to current market conditions. In the evolving venture capital market, our experience with PIPEs, spin-outs and recapitalizations, combined with our proactive research to identify contrarian opportunities and 'special situations' helps us exploit value dislocations and accelerate returns."

Probitas Partners acted as exclusive placement agent and financial advisor to Longitude Capital in connection with the offering. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 27

NIH’s I-Corps boot camp aims to transform researchers into better businesspeople before they launch products

Covance, Frenova form partnership to share patient databases, find effective treatments for renal disease

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs